Skip to main content

Table 1 Patient chararcteristics-patients receiving ASCT

From: Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

  Patients ≤ 60 years of age Patients 61–65 years of age
N (%) N (%)
M-Component
 IgG κ 76 (36,1) 31 (37,5)
 IgG λ 24 (11,9) 11 (13,8)
 IgA κ 27 (12,0) 13 15,9)
 IgA λ 12 (6,6) 7 (8,3)
 light chain κ 42 (19,1) 10 (13,2)
 light chain λ 16 (7,3) 5 (6,3)
 non secretory 13 (6,0) 2 (2,5)
 biclonal 2 (1,0) 0 (0)
 no information 0 2 (2,5)
Stage Durie&Salmon
 IA 55 (26,4) 22 (27,1)
 IB 5 (2,4) 2 (2,4)
 IIA 82 (38,9) 33 (41,0)
 IIB 16 (7,4) 4 (5,0)
 IIIA 40 (18,5) 17 (21,2)
 IIIB 14 (6,4) 3 (3,3)
Stage ISS
 ISS I 65 (31,0) 21 (26,3)
 ISS II 40 (18,5) 18 (22,6)
 ISS III 39 (18,1) 19 (23,8)
 No information*) 68 (32,4) 23 (27,3)
  1. *)β-globulin missing